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Background: Peripheral Diabetic Neuropathy (PDN) and cognitive impairment are complications of Diabetes
Mellitus (DM) that seem to share several underlying mechanisms. The aim of this study was to investigate whether
diabetic patients would have worse cognitive function than non diabetic individuals and within diabetic patients,
whether those with PDN would present an even more significant cognitive impairment.
Findings: Ninety four (94) outpatients with Type 2 DM were sequentially evaluated. Also, Fifty four (54) healthy
individuals were sequentially selected to match the diabetic group. For the assessment of neuropathy, Portuguese
versions of the Neuropathy Disability Score (NDS) and Neuropathy Symptom Score (NSS) were used. Global cognitive
function was assessed by using the Portuguese Version of the Mini-Mental State Examination (MMSE), Trail Making Tests A
and B and Verbal Fluency Test. Significantly lower scores were found in the Type 2 DM group in comparison to control
group in the MMSE (25.7 [16–30] vs 27.6 [19–30]; p <0.001). Within T2DM group, forty five (45) patients were diagnosed
with PDN. No differences were found between patients with and without PDN in all cognitive tests (p >0.05 in all
comparison). No correlation was also found among NSS, NDS and any of the cognitive tests.
Conclusion: Although diabetic patients do have a worse cognitive function, this impairment does not seem to be related
to the presence and/or severity of PDN.
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Patients with poorly controlled Type 2 Diabetes Mellitus
(T2DM) usually develop complications, particularly micro-
vascular. Among these, Diabetic Neuropathy (DN) is char-
acterized by progressive nerve destruction, leading to
innumerous different clinical presentations, including Per-
ipheral Diabetic Neuropathy (PDN) [1]. In the past years,
cognitive impairment has also been demonstrated as a
complication of T2DM [2]. Although the pathogenesis has
been linked mainly to impaired insulin signaling [3], some
studies have suggested that it may also share multiple
pathogenic pathways with PDN, including oxidative stress,* Correspondence: rom_br@yahoo.com
Instituto Estadual de Diabetes e Endocrinologia (IEDE), Pontificia
Universidade Católica do Rio de Janeiro (PUC-RJ), Rua Moncorvo Filho 90,
CEP 20211-340 Rio de Janeiro, RJ, Brazil
© 2015 Moreira et al. This is an Open Access a
(http://creativecommons.org/licenses/by/4.0),
provided the original work is properly credited
creativecommons.org/publicdomain/zero/1.0/inflammation, dyslipidemia, among others [4–8]. Consider-
ing the coexistence of some of these mechanisms in pa-
tients with PDN, it would be interesting to speculate
whether patients with peripheral neuropathy would also ex-
hibit some degree of central nervous system lesion. There-
fore, we hypothesized that diabetic patients would have
worse cognitive function than non diabetic individuals and
that within diabetic patients, those with PDN would
present an even more significant cognitive impairment.Patients and Methods
Study population
Ninety four (94) outpatients with T2DM were sequen-
tially evaluated in the Instituto Estadual de Diabetes e
Endocrinologia do Rio de Janeiro, a tertiary referral cen-
ter, from September 2011 to August 2012.rticle distributed under the terms of the Creative Commons Attribution License
which permits unrestricted use, distribution, and reproduction in any medium,
. The Creative Commons Public Domain Dedication waiver (http://
) applies to the data made available in this article, unless otherwise stated.
Table 1 Socio-demographic characteristics of a sample of patients





(n = 54) (n = 94) p
Age (years) 65.8 66.4 0.21
(61–84) (60–75)
Gender (Female) 52 87 0.48
Educational Level (years) 7.6 7.5 0.83
(4–16) (2–18)
Marital Status (Married) 26 49 0.73
Income (Minimun Wage) 2 2.2 0.56
(0.5–4.0) (1.0–8.0)
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least 04 years of formal education, more than 2 years of
T2DM diagnosis and ability to understand the proce-
dures of the study.
Exclusion criteria included previous amputation, blind-
ness, end stage kidney disease, end stage liver disease, previ-
ous diagnosis of dementia, use of cholinesterase inhibitors,
diagnosis of major psychiatric conditions (defined by the
patient according to the need of psychiatric treatment),
past or present coronary artery disease (including Myocardial
Infarction, coronary revascularization, stable or unstable
angina), cerebrovascular disease (including stroke and tran-
sitory ischemic attack) and symptomatic peripheral vascular
disease. Patients were also excluded if they had any med-
ical diseases or neurologic disorders that could be associ-
ated with neuropathy. The protocol was approved by the
Ethics Committee of the Institution and written informed
consent was obtained from each patient after the proce-
dures involved in the study were fully explained.
Fifty four (54) healthy individuals were sequentially se-
lected to match the diabetic group by age, gender and educa-
tional level. These individuals were all employees in the
hospital. A complete medical history was obtained from
these individuals to confirm that they have no relevant med-
ical condition. Inclusion and exclusion criteria were the same
as for the diabetic group, except that patients should not
have T2DM.
Neuropathy assessment
All patients were carefully examined by an experienced
endocrinologist and provided a detailed medical history at
baseline evaluation. For the assessment of neuropathy, Por-
tuguese versions of the Neuropathy Disability Score (NDS)
and Neuropathy Symptom Score (NSS) were used. The
final score was the mean value of their evaluations. NSS
and NDS are two of the most common instruments used
for the assessment of SDPN in clinical practice and medical
research. NSS and NDS have already been adequately
translated into Portuguese and are both considered to be
reliable instruments [9]. Moreover, they cover both symp-
toms and signs of SDPN. The NDS and NSS versions used
in this study were derived from the version modified by
Young et al. [10]. NDS was obtained with the examination
of the ankle reflex, vibration, pin-prick, and temperature
sensation (cold tuning fork) in the big toe. The total max-
imum abnormal score on this scale was 10. A score of 3–5
was regarded as evidence of mild neuropathic signs, 6–8 as
evidence of moderate signs and a score of 9–10 was
regarded as evidence of severe signs of neuropathy. The
NSS was based on questioning the patients about their ex-
periences of pain or discomfort in the legs. The maximum
symptom score on this scale was 9. A symptom score of 3–
4 was regarded as mild symptoms, a score of 5–6 as moder-
ate symptoms and a score of 7–9 as severe symptoms ofneuropathy. The minimum acceptable criteria for a diagno-
sis of peripheral neuropathy were: moderate signs with or
without symptoms, or mild signs with moderate symptoms.
Mild signs alone or with mild symptoms were not consid-
ered to be an adequate parameter for a diagnosis of periph-
eral neuropathy.
Cognition assessment
Global cognitive function was assessed by using the
Portuguese Version of the Mini-Mental State Examination
(MMSE) [11]. Trail Making Tests A (TMT-A), B (TMT-B)
and Verbal Fluency Test (VFT - Animals) were also used
to evaluate general aspects of cognition.
Statistical analysis
Statistical analysis was performed with GraphPad InStat
3.00 (GraphPad Software, San Diego, CA, USA). Compari-
son between groups was performed using Mann–Whitney
test and Fisher’s exact test to analyze categorical data. For
non parametric variables, data are presented as median
[lower limit–upper limit]. Spearman test was used for cor-
relation analysis of nonparametric variables. The level of
statistical significance was 5 %.
Results
One hundred (100) patients with DM and 60 healthy in-
dividuals were invited to join the study. Six patients in
both group refused to participate.
Initially, patients with T2DM were compared with the
control group. No differences were found in age, gender
or years of formal education (Table 1). When cognitive
function was evaluated, significantly lower scores were
found in the T2DM group in comparison to control group
in the MMSE (25.7 [16–30] vs 27.6 [19–30]; p <0.001). No
differences were found in TMT-A (67.8 seconds in T2DM
[30–186] vs 74.2 in control group [25–238]; p = 0.24) and
VFT (13.7 words in T2DM [8–20] vs 13.4 in control
group [6–21]; p = 0.58). A trend toward significance were
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Within T2DM group, forty five (45) patients were di-
agnosed with PDN. Patients with and without PDN were
compared and no differences were observed in age, gen-
der, educational level, marital status and disease duration
(data not shown). Also, no differences were found be-
tween patients with and without PDN in all cognitive tests
(Table 2). No correlation was also found among NSS,
NDS and any of the cognitive tests (data not shown).
Discussion
The relationship between T2DM, cognitive impairment
and Alzheimer’s Disease seems strong. Although some
mechanisms linking these diseases have already been estab-
lished, several points are still controversial [3, 12]. In par-
ticular, it remains to be determined whether cognitive
impairment could have any relationship with other micro-
vascular complications of DM, particularly DN. In line
with this, we investigated whether the presence of DPN
would be associated with cognitive functioning. Our most
relevant findings were: i–patients with T2DM have a
significant worse cognitive function than non-diabetic
individuals; ii–no differences in cognitive function were
found in T2DM patients with DPN in comparison to
those without DPN and iii–no correlation was found
between signs and/or symptoms of DPN and cognitive
function.
Different mechanisms have already been proposed for
DN pathogenesis. Some of these mechanisms have already
been linked to the pathogenesis of cognitive impairment,
including oxidative stress, microvascular vasculopathy, in-
flammation, dyslipidemia, among others [4–8]. Although
these may be considered common mechanisms for both
DN and cognitive impairment, no correlation between
these two complications was found in our study. Moreover,
since most of these variables were not evaluated in thisTable 2 Comparison of cognitive function in type 2 diabetic






(n = 48) (n = 45) p
Mini-Mental State Examination 26.0 25.5 0.58
(16–30) (16–30)
Trail Making Test-A (seconds) 75.7 72.6 0.22
(27–142) (25–238)
Trail Making Test-B (seconds) 153.5 163.4 0.47
(40–294) (55–296)
Verbal Fluency Test 13.8 13.0 0.23
(8–21) (6–19)study, it is not possible to determine whether any of these
mechanisms could be related to DN and/or cognitive im-
pairment in specific patients. Further studies are necessary
to clarify this issue.
There are some explanations for our findings. First,
the diagnosis of DPN was based only in clinical scales.
Although these scales are widely used, it would be very
interesting to compare findings from cognitive with
nerve conduction tests. It should be noted that there
were patients who scored less than 24 in MMSE, sug-
gesting that individuals with dementia may have been in-
cluded in the study. This might be of great relevance,
particularly because NDS and NSS have not been vali-
dated in this specific population. NDS is based on the
assessment of peripheral sensitivity, which completely
depends on the ability of the patient to understand what
is been asked and what is been done by the examiner.
The same considerations can also be applied to NSS,
which depends on the comprehension of specific questions
to determine different symptoms. It is impossible to evalu-
ate, at this moment, how cognitive impairment would in-
fluence the results of these scores (i.e. false-positives or
false-negatives). However, it is worthy noticing that these
scales have already been used in populations that included
older individuals and dementia has not been evaluated
in these studies (9,10). Second, the cognitive impairment
that occurs in T2DM may have completely different mecha-
nisms from the ones that affect peripheral nerves. Although
these complications do share some similarities (as dis-
cussed above), multiple and individual components may
play an important role in determining who will develop
central and who will develop peripheral nerve destruction.
Third, the vast majority of patients included in this study
were women. Further studies are necessary to clarify whether
the same results would also be demonstrated in men. Fi-
nally, there are other variables that could be of great rele-
vance for the association of PDN and cognitive impairment,
including Body Mass Index, Glycemic Control (including
hypoglycemia), and lipid profile. Unfortunately, these vari-
ables were not accessed in this study.
In summary, cognitive impairment seems to be more
severe in T2DM than in non-diabetic individuals. Although
diabetic patients do have a worse cognitive function, this
decline does not seem to be related to the presence and/or
severity of DPN. Further studies are necessary to clarify
whether these findings would also be applicable to different
populations, with different stages of cognitive impairment
and neuropathy.
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